ArticleScience (New York, N.Y.)2018
Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells.
Registry-linked trialAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05620004 (Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy), which is not on this map. Cited by 894 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
894citing papers in PubMed, 2 pooled it
47.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT05620004 phase1 / phase2unknown statusnot on this mapstarted 2021, after this paper: background citation
Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy: a Randomized Controlled, Single-center Clinical Trial
Who cites it
894 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,438 citations in OpenAlex.
- The lung-gut-brain axis in non-small-cell lung cancer: a narrative review with a systematic search of three signaling pathways.Frontiers in immunology · 2026Pooled it
- Metabolic phenotyping combined with transcriptomics metadata fortifies the diagnosis of early-stage Hepatocellular carcinoma.Journal of advanced research · 2025Pooled it
- Microbiome-Modulating Effects of Heat-TreatedJournal of microbiology and biotechnology · 2026Trial
- Testosterone administration partially modulates gut microbiota responses to severe energy deficit.American journal of physiology. Endocrinology and metabolism · 2026Trial
- Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study.Signal transduction and targeted therapy · 2026Trial
- Trial
- Association between gut microbiota characteristics and therapeutic efficacy of multimodal combination therapy in hepatocellular carcinoma with portal vein tumor thrombus: a secondary analysis of a prospective phase II trial.Frontiers in immunology · 2026Trial
- Trial
- Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study.Journal for immunotherapy of cancer · 2025Trial
- Longitudinal gut microbiome dynamics are associated with clinical outcome and toxicity during ibrutinib therapy.Gut microbes · 2026Article
- The gut microbiome-bile acid-FXR interplay: a pivotal axis in metabolic and gastrointestinal diseases.Gut microbes · 2026Review
- Metabolites and cancer metastasis.Oncogene · 2026Review
- Microbial cues and T cell immunity: deciphering their interactions in chronic liver disease.Experimental & molecular medicine · 2026Review
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- Bile acid signaling in health and disease.Molecular biomedicine · 2026Review
- Sex-Dependent Microbial and Host Profiles Following Fecal Microbiota andGut and liver · 2026Article
- HDCA suppresses exosomal lncRNA MSTRG171708 release to inhibit Treg-mediated immunometabolism in hepatocellular carcinoma.Molecular biomedicine · 2026Article
- Mucosal immunity: mechanism and application in cancer immunotherapy.Journal of hematology & oncology · 2026Review
- The Emerging Challenge of Non-Cirrhotic MASLD-Related Hepatocellular Carcinoma: Etiology, Immunopathology, and Precision Oncology.Liver cancer · 2026Review
- Microbial Signals in Cancer: Dissecting Host-Microbiota-Tumor Interactions and Potential Therapeutic Strategy.MedComm · 2026Review
834 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
23 authors at 5 institutions in 3 countries.
Chi MaGastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-4171-0813
Miaojun HanGastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Bernd HeinrichGastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-0033-2462
Qiong FuGastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-6796-9084
Qianfei ZhangGastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Milan SandhuGastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
David AgdashianGastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-5912-8031
Masaki TerabeVaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-1777-0189
Jay A BerzofskyVaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-0342-3194
Valerie FakoLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-1532-5153
Thomas RitzInstitute of Pathology, University Hospital RWTH Aachen, Aachen 52074, Germany.
Thomas LongerichInstitute of Pathology, University Hospital RWTH Aachen, Aachen 52074, Germany.
Casey M TheriotDepartment of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607, USA.
John A McCullochCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Soumen RoyCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Wuxing YuanCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Vishal ThovaraiCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-6546-3266
Shurjo K SenCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-5781-721X
Mathuros RuchirawatChulabhorn Research Institute, Bangkok, Thailand.ORCID 0000-0001-6402-2442
Firouzeh KorangyGastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Xin Wei WangLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Giorgio TrinchieriCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Tim F GretenGastrointestinal Malignancy Section, Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. tim.greten@nih.gov.ORCID 0000-0002-0806-2535
National Institutes of Health · USChulabhorn Research Institute · THHeidelberg University · DENorth Carolina State University · USRWTH Aachen University · DE
Funding
Analysis of myeloid derived suppressor cells in miceZIABC011345 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GRETEN, TIM · 2010 to 2025
$19.5MClinical protocols for the treatment of GI cancerZIABC011343 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GRETEN, TIM · 2010 to 2025
$4.8MAntigen-specific T-cell activation, vaccines for CancerZ01SC004020 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI BERZOFSKY, JAY A · 1996 to 2008
$3.8MTargeted bacterial restoration of colonization resistance against C. difficileR35GM119438 · NIGMS · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI THERIOT, CASEY MICHELLE · 2016 to 2020
$1.6MThe role of cancer stem cells in liver cancer heterogeneity and subtypesZ01BC010876 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN · 2008 to 2008
$490kIntramural NIH HHS Z01 BC010876Intramural NIH HHS Z01 SC004020Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011345NIGMS NIH HHS R35 GM119438
Abstract
Primary liver tumors and liver metastasis currently represent the leading cause of cancer-related death. Commensal bacteria are important regulators of antitumor immunity, and although the liver is exposed to gut bacteria, their role in antitumor surveillance of liver tumors is poorly understood. We found that altering commensal gut bacteria in mice induced a liver-selective antitumor effect, with an increase of hepatic CXCR6
Indexed as
Immunologic SurveillanceAnimalsBile Acids and SaltsChemokine CXCL16ClostridiumGastrointestinal MicrobiomeHumansLiverLiver NeoplasmsLymphocyte DepletionMiceMice, Inbred C57BLNatural Killer T-CellsNeoplasm MetastasisReceptors, CXCR6Bile Acids and SaltsChemokine CXCL16Receptors, CXCR6
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05620004ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.